Advertisement

Effects of ADIPOQ polymorphisms on PCOS risk: a meta-analysis

  • Zhengling Liu
  • Zengyan Wang
  • Changhong Hao
  • Yonghui Tian
  • Jingjing Fu
Open Access
Research
  • 118 Downloads

Abstract

Background

Whether adiponectin (ADIPOQ) polymorphisms are associated with the risk of polycystic ovary syndrome (PCOS) remain controversial. Therefore, we performed this study to better explore correlations between ADIPOQ polymorphisms and PCOS risk.

Methods

Literature retrieve was conducted in PubMed, Medline and Embase. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.

Results

Eighteen studies were enrolled for analyses. Pooled overall analyses showed that rs1501299 polymorphism was significantly associated with PCOS risk (recessive model: p = 0.02, OR = 0.77, 95%CI 0.62–0.95; allele model: p = 0.001, OR = 1.15, 95%CI 1.06–1.26). Further subgroup analyses according to ethnicity of participants revealed that rs1501299 and rs2241766 polymorphisms were both significantly correlated with PCOS risk in Caucasians. In addition, rs1501299 polymorphism was also significantly correlated with PCOS risk in East Asians.

Conclusions

Our findings indicated that rs1501299 and rs2241766 polymorphisms might serve as genetic biomarkers of PCOS in certain ethnicities.

Keywords

Adiponectin (ADIPOQGene polymorphisms Polycystic ovary syndrome (PCOS) Meta-analysis 

Abbreviations

ADIPOQ

Adiponectin

HWE

Hardy-Weinberg equilibrium

NOS

Newcastle-Ottawa scale

PCOS

Polycystic ovary syndrome

Background

Polycystic ovary syndrome (PCOS), featured by oligomenorrhea, polycystic ovaries, anovulatory infertility, hyperandrogenism, insulin resistance or hyperinsulinemia, and an elevated risk of multiple metabolic diseases, is an extremely common reproductive endocrine disorder, with an estimated prevalence of approximately 5–10% in women of childbearing age [1, 2, 3]. Although the exact cause of PCOS remains unclear, mounting evidence supports that genetic factors play vital roles in its pathogenesis. First, family clustering of PCOS was not uncommon, and first-degree relatives of PCOS patients suffered an increased risk of developing PCOS and its associated disorders [4, 5]. Second, various genetic variants were found to be correlated with a higher PCOS risk [6]. However, PCOS is a highly heterogeneous disorder and genetic determinants underlying PCOS are still poorly understood [7, 8].

Adiponectin (ADIPOQ), a multifunctional adipocytokine that is primarily secreted by adipocytes, plays a pivotal role in regulating energy and material metabolism [9]. Previous studies showed that expression level of adiponectin was significantly reduced in patients with various metabolic disorders such as diabetes, obesity and insulin resistance, which suggested that adipoenctin might be involved in the pathogenesis of above-mentioned diseases [10, 11]. Considering the metabolic nature of PCOS and the fact that the expression levels of adiponectin and its receptors in female reproductive organs (ovary and uterus) vary in different phases of oestrous cycle [12], it is biologically plausible that adiponectin might also be implicated in the occurrence and development of PCOS.

Adiponectin is encoded by the ADIPOQ gene located on chromosome 3q27 [13]. It was evident that two common functional ADIPOQ polymorphisms, rs1501299 and rs2241766, were correlated with altered serum concentration of adiponectin [14, 15]. As a result, these two polymorphisms were thought to be ideal genetic biomarkers of multiple metabolic disorders including PCOS. So far, several studies already investigated associations between these ADIPOQ polymorphisms and PCOS risk, but the results of these studies were controversial [16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]. Therefore, we performed the present meta-analysis to better explore potential roles of ADIPOQ polymorphisms in PCOS.

Methods

Literature search and inclusion criteria

This meta-analysis was adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline [34]. Potentially related literatures (published before September 2018) were retrieved from PubMed, Medline and Embase using the following searching strategy: (adiponectin OR ADIPOQ) AND (polymorphism OR variant OR mutation OR genotype OR allele) AND (polycystic ovary syndrome OR PCOS). Furthermore, the references of retrieved articles were also screened for other potentially relevant studies.

To test the research hypothesis of this meta-analysis, included studies must meet all the following criteria: (1) case-control study on correlations between ADIPOQ polymorphisms and PCOS risk; (2) provide genotypic and/or allelic frequency of investigated ADIPOQ polymorphisms in cases and controls; (3) full text in English or Chinese available. Studies were excluded if one of the following criteria was fulfilled: (1) not relevant to ADIPOQ polymorphisms and PCOS; (2) case reports or case series; (3) abstracts, reviews, comments, letters and conference presentations. For duplicate publications, we only included the study with the largest sample size for analyses.

Data extraction and quality assessment

The following data were extracted from included studies: (1) the name of the first author; (2) publication time; (3) country and ethnicity; (4) sample size; and (5) genotypic distributions of ADIPOQ polymorphisms in cases and controls. Additionally, the probability value (p value) of Hardy-Weinberg equilibrium (HWE) was also calculated. When necessary, we wrote to the corresponding authors for raw data. We used the Newcastle-Ottawa scale (NOS) to assess the quality of eligible studies [35]. This scale has a score range of zero to nine, and studies with a score of more than seven were thought to be of high quality. Two reviewers conducted data extraction and quality assessment independently. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

Statistical analysis

All statistical analyses were conducted with Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate strength of associations between ADIPOQ polymorphisms and PCOS risk in all possible genetic models, and p values ≤0.05 were considered to be statistically significant. Between-study heterogeneities were evaluated with I2 statistic. If I2 was greater than 50 %, random-effect models (REMs) would be used to pool the data. Otherwise, fixed-effect models (FEMs) would be employed for synthetic analyses. Subgroup analyses by ethnicity were subsequently performed. Sensitivity analyses were conducted to examine the stability of synthetic results. Funnel plots were used to evaluate possible publication bias.

Results

Characteristics of included studies

We found 331 potential relevant articles. Among these articles, a total of 18 eligible studies were finally included for synthetic analyses (see Fig. 1). The NOS score of eligible articles ranged from 7 to 8, which indicated that all included studies were of high quality. Baseline characteristics of included studies were shown in Table 1.
Fig. 1

Flowchart of study selection for the present study

Table 1

The characteristics of included studies

First author, year

Country

Ethnicity

Age (years)

Case/Control

Sample size

Genotype distribution

P-value for HWE

NOS score

Cases Controls

rs1501299 G/T

    

GG/GT/TT

GG/GT/TT

  

 Alfaqih 2018 [16]

Jordon

West Asian

23.9/24.2

154/151

62/77/15

64/54/33

0.002

8

 Czeczuga-Semeniuk 2018 [17]

Poland

Caucasian

24.6/23.2

294/78

156/117/21

25/49/4

0.002

8

 Escobar-Morreale 2006 [19]

Spain

Caucasian

NA

76/40

30/39/7

15/21/4

0.390

7

 Heinonen 2005 [21]

Finland

Caucasian

NA

143/245

77/58/8

110/110/25

0.744

7

 Li 2011 [22]

Korea

East Asian

NA

144/159

61/73/10

48/87/24

0.131

7

 Nambiar 2016 [23]

India

West Asian

28.6/31.1

282/200

94/165/23

86/99/15

0.060

8

 Pau 2013 [25]

USA

Mixed

NA

525/472

NA

NA

NA

7

 Radavelli-Bagatini 2013 [26]

Brazil

Mixed

NA

80/1500

42/27/11

671/672/157

0.556

7

 Ramezani Tehrani 2013 [27]

Iran

West Asian

26.6/30.8

186/156

92/76/18

77/71/8

0.100

7

 Ranjzad 2012 [28]

Iran

West Asian

27.1/31.1

181/181

92/77/12

91/79/11

0.254

8

 San Millán 2004 [29]

Spain

Caucasian

24.6/31.1

72/42

28/34/10

18/20/4

0.643

7

 Xita 2005 [30]

Greece

Caucasian

23.7/24.8

100/140

39/49/12

52/73/15

0.152

7

 Yoshihara 2009 [31]

Japan

East Asian

29.1/29.8

38/97

19/15/4

58/24/15

< 0.001

8

 Zhang 2008 [32]

China

East Asian

28.7/29.6

120/120

56/46/18

41/50/29

0.083

8

 Zhang 2015 [33]

China

East Asian

27.0/27.2

207/192

119/78/10

95/75/22

0.229

7

rs2241766 T/G

    

TT/TG/GG

TT/TG/GG

  

 Alfaqih 2018 [16]

Jordon

West Asian

23.9/24.2

154/149

92/48/14

93/42/14

0.008

8

 Czeczuga-Semeniuk 2018 [17]

Poland

Caucasian

24.6/23.2

294/78

255/39/0

62/16/0

0.313

8

 Demirci 2010 [18]

Turkey

Caucasian

24.1/23.8

96/93

70/20/6

74/16/3

0.091

8

 Escobar-Morreale 2006 [19]

Spain

Caucasian

NA

76/40

55/20/1

26/13/1

0.673

7

 Haap 2005 [20]

Germany

Caucasian

27.4/38.9

53/542

38/8/7

414/112/16

0.016

8

 Heinonen 2005 [21]

Finland

Caucasian

NA

143/245

125/17/1

222/22/1

0.572

7

 Li 2011 [22]

Korea

East Asian

NA

144/159

79/59/6

72/84/3

< 0.001

7

 Nambiar 2016 [23]

India

West Asian

28.6/31.1

282/200

213/60/9

156/40/4

0.453

8

 Panidis 2004 [24]

Greece

Caucasian

23.4/29.4

132/100

92/33/7

81/17/2

0.340

7

 Radavelli-Bagatini 2013 [26]

Brazil

Mixed

NA

80/1500

64/14/2

1122/356/22

0.297

7

 Ramezani Tehrani 2013 [27]

Iran

West Asian

26.6/30.8

186/156

142/42/2

106/46/4

0.707

7

 Ranjzad 2012 [28]

Iran

West Asian

27.1/31.1

181/181

144/34/2

121/54/6

0.993

8

 San Millán 2004 [29]

Spain

Caucasian

24.6/31.1

72/42

48/22/2

29/12/1

0.853

7

 Xita 2005 [30]

Greece

Caucasian

23.7/24.8

100/140

77/23/0

106/30/4

0.306

7

 Yoshihara 2009 [31]

Japan

East Asian

29.1/29.8

38/97

19/19/0

53/29/15

0.004

8

 Zhang 2008 [32]

China

East Asian

28.7/29.6

120/120

57/54/9

74/42/4

0.504

8

 Zhang 2015 [33]

China

East Asian

27.0/27.2

207/192

106/84/17

98/75/19

0.409

7

PCOS Polycystic ovary syndrome, HWE Hardy-Weinberg equilibrium, NOS Newcastle-Ottawa scale, NA Not available

Overall and subgroup analyses

To investigate potential correlations between ADIPOQ polymorphisms and PCOS risk, fifteen studies about rs1501299 polymorphism and seventeen studies about rs2241766 polymorphism were included for pooled analyses. A significant association with PCOS risk was detected for rs1501299 (recessive model: p = 0.02, OR = 0.77, 95%CI 0.62–0.95; allele model: p = 0.001, OR = 1.15, 95%CI 1.06–1.26) polymorphism in overall analyses. Further subgroup analyses according to ethnicity of participants revealed that rs1501299 and rs2241766 polymorphisms were both significantly correlated with PCOS risk in Caucasians. In addition, rs1501299 polymorphism was also significantly correlated with PCOS risk in East Asians (see Table 2).
Table 2

Results of overall and subgroup analyses for ADIPOQ gene polymorphisms and PCOS

Population

Sample size

Dominant comparison

Recessive comparison

Additive comparison

Allele comparison

P value

OR (95%CI)

I2 statistic

P value

OR (95%CI)

I2 statistic

P value

OR (95%CI)

I2 statistic

P value

OR (95%CI)

I2 statistic

rs1501299 G/T

 

GG vs. GT + TT

TT vs. GG + GT

GT vs. GG + TT

G vs. T

Overall

2602/3773

0.10

1.17 (0.97–1.42)

52%

0.02

0.77 (0.62–0.95)

46%

0.52

0.94 (0.76–1.15)

58%

0.001

1.15 (1.06–1.26)

43%

Caucasian

685/545

0.007

1.40 (1.09–1.79)

42%

0.79

0.94 (0.62–1.45)

0%

0.01

0.73 (0.58–0.93)

48%

0.03

1.22 (1.02–1.46)

22%

East Asian

509/568

0.006

1.41 (1.10–1.81)

37%

0.0003

0.48 (0.32–0.71)

0%

0.76

0.96 (0.75–1.23)

17%

0.0001

1.44 (1.20–1.73)

2%

West Asian

803/688

0.19

0.87 (0.71–1.07)

4%

0.88

0.95 (0.47–1.89)

70%

0.30

1.19 (0.85–1.68)

62%

0.52

0.95 (0.81–1.11)

31%

rs2241766 T/G

 

TT vs. TG + GG

GG vs. TT + TG

TG vs. TT + GG

T vs. G

Overall

2358/4034

0.63

1.03 (0.91–1.18)

46%

0.54

1.10 (0.81–1.50)

41%

0.44

0.95 (0.83–1.09)

44%

1.00

1.00 (0.84–1.19)

54%

Caucasian

966/1280

0.32

0.89 (0.70–1.12)

22%

0.04

1.93 (1.05–3.56)

26%

0.84

1.03 (0.80–1.31)

6%

0.11

0.84 (0.68–1.04)

46%

East Asian

509/568

0.74

0.93 (0.62–1.40)

61%

0.86

1.10 (0.40–3.02)

59%

0.54

1.17 (0.71–1.93)

73%

0.95

0.99 (0.73–1.35)

58%

West Asian

803/686

0.31

1.22 (0.83–1.80)

65%

0.56

0.85 (0.49–1.47)

8%

0.31

0.83 (0.59–1.18)

53%

0.32

1.19 (0.84–1.69)

67%

OR Odds ratio, CI Confidence interval, NA Not available. PCOS Polycystic ovary syndrome

The values in bold represent there is statistically significant differences between cases and controls

Sensitivity analyses

We performed sensitivity analyses by excluding studies that deviated from HWE. No alterations of results were detected in sensitivity analyses, which suggested that our findings were statistically reliable.

Publication biases

Publication biases were evaluated with funnel plots. We did not find obvious asymmetry of funnel plots in any comparisons, which indicated that our findings were unlikely to be impacted by severe publication biases.

Discussion

To the best of our knowledge, this is so far the most comprehensive meta-analysis on correlations between ADIPOQ polymorphisms and PCOS risk. Our overall and subgroup analyses demonstrated that rs1501299 and rs2241766 polymorphisms were both significantly correlated with PCOS risk in Caucasians. Moreover, rs1501299 polymorphism was also significantly correlated with PCOS risk in East Asians.

There are several points that need to be addressed about this meta-analysis. Firstly, previous experimental studies showed that mutant alleles of investigated polymorphisms were correlated with decreased adiponectin generation, which may partially explain our positive findings [14, 15]. Secondly, the pathogenic mechanism of PCOS is highly complex, and hence it is unlikely that a single gene polymorphism could significantly contribute to its development. As a result, to better illustrate potential correlations of certain gene polymorphisms with PCOS, we strongly recommend further studies to perform haplotype analyses and explore potential gene-gene interactions.

As with all meta-analysis, this study certainly has some limitations. First, our results were derived from unadjusted analyses due to lack of raw data, and lack of further adjusted analyses for potential confounding factors may impact the reliability of our findings [36]. Second, obvious heterogeneities were found in several subgroups, which indicated that the controversial results of included studies could not be fully explained by differences in ethnic background, and other baseline characteristics of participants may also contribute to between-study heterogeneities [37]. Third, associations between ADIPOQ polymorphisms and PCOS risk may also be modified by gene-gene and gene-environmental interactions. However, most eligible studies ignore these potential interactions, which impeded us to perform relevant analyses accordingly [38]. To sum up, our findings should be cautiously interpreted on account of above mentioned limitations.

Conclusions

In conclusion, our meta-analysis suggested that rs1501299 and rs2241766 polymorphisms might serve as genetic biomarkers of PCOS in certain ethnicities. However, further well-designed studies are still warranted to confirm our findings.

Notes

Acknowledgments

None.

Funding

None.

Availability of data and material

The current study was based on results of relevant published studies.

Informed consent

For this type of study formal consent is not required.

Authors’ contributions

ZL and CH conceived of the study, participated in its design. ZL and ZW conducted the systematic literature review. YT and JF performed data analyses. ZL and CH drafted the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Pasquali R, Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann N Y Acad Sci. 2006;1092:158–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97.CrossRefPubMedGoogle Scholar
  4. 4.
    Amato P, Simpson JL. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:707–18.CrossRefPubMedGoogle Scholar
  5. 5.
    Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab. 1999;84:38–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Ioannidis A, Ikonomi E, Dimou NL, Douma L, Bagos PG. Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. Mol Genet Metable. 2010;99:174–83.CrossRefGoogle Scholar
  7. 7.
    Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3:103–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Luque-Ramirez M, San Millan JL, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. Clin Chim Acta. 2006;366:14–26.CrossRefPubMedGoogle Scholar
  9. 9.
    Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: a potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018;39:151–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Dobrzyn K, Smolinska N, Kiezun M, Szeszko K, Rytelewska E, Kisielewska K, Gudelska M, Kaminski T. Adiponectin: a new regulator of female reproductive system. Int J Endocrinol. 2018:7965071.Google Scholar
  11. 11.
    Frankenberg ADV, Reis AF, Gerchman F. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review. Arch Endocrinol Metab. 2017;61:614–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017;18:E1321.CrossRefPubMedGoogle Scholar
  13. 13.
    Xian L, He W, Pang F, Hu Y. ADIPOQ gene polymorphisms and susceptibility to polycystic ovary syndrome: a HuGE survey and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2012;161:117–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Dahlman I, Arner P. Genetics of adipose tissue biology. Prog Mol Biol Transl Sci. 2010;94:39–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Al Hannan FA, O'Farrell PA, Morgan MP, Tighe O, Culligan KG. Associations between single-nucleotide polymorphisms of ADIPOQ, serum adiponectin and increased type 2 diabetes mellitus risk in Bahraini individuals. East Mediterr Health J. 2016;22:611–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Alfaqih MA, Khader YS, Al-Dwairi A, Alzoubi A, Al-Shboul O, Hatim A. Lower Levels of Serum Adiponectin and the T Allele of rs1501299 of the ADIPOQ Gene Are Protective against Polycystic Ovarian Syndrome in Jordan. Korean J Fam Med. 2018;39:108–13.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Czeczuga-Semeniuk E, Galar M, Jarząbek K, Kozłowski P, Sarosiek NA, Wołczyński S. The preliminary association study of ADIPOQ, RBP4, and BCMO1 variants with polycystic ovary syndrome and with biochemical characteristics in a cohort of polish women. Adv Med Sci. 2018;63:242–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Demirci H, Yilmaz M, Ergun MA, Yurtcu E, Bukan N, Ayvaz G. Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters. Gynecol Endocrinol. 2010;26:348–55.CrossRefPubMedGoogle Scholar
  19. 19.
    Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchón R, Luque-Ramírez M, San Millán JL. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular geneticstudy. Hum Reprod. 2006;21:2257–65.CrossRefPubMedGoogle Scholar
  20. 20.
    Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, Wallwiener D, Stumvoll M, Häring HU, Fritsche A. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2005;113:275–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Heinonen S, Korhonen S, Helisalmi S, Koivunen R, Tapanainen J, Hippeläinen M, Laakso M. Associations between two single nucleotide polymorphisms in the adiponectin geneand polycystic ovary syndrome. Gynecol Endocrinol. 2005;21:165–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Li L, Yun JH, Lee JH, Song S, Choi BC, Baek KH. Association study of +45G15G(T/G) and +276(G/T) polymorphisms in the adiponectin gene in patients with polycystic ovary syndrome. Int J Mol Med. 2011;27:283–7.PubMedGoogle Scholar
  23. 23.
    Nambiar V, Vijesh VV, Lakshmanan P, Sukumaran S, Suganthi R. Association of adiponectin and resistin gene polymorphisms in south Indian women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;200:82–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Panidis D, Kourtis A, Kukuvitis A, Farmakiotis D, Xita N, Georgiou I, Tsatsoulis A. Association of the T45G polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of Delta4-androstenedione. Hum Reprod. 2004;19:1728–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Pau C, Saxena R, Welt CK. Evaluating reported candidate gene associations with polycystic ovary syndrome. Fertil Steril. 2013;99:1774–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Radavelli-Bagatini S, de Oliveira IO, Ramos RB, Santos BR, Wagner MS, Lecke SB, Gigante DP, Horta BL, Spritzer PM. Haplotype TGTG from SNP 45T/G and 276G/T of the adiponectin gene contributes to risk of polycystic ovary syndrome. J Endocrinol Investig. 2013;36:497–502.Google Scholar
  27. 27.
    Ramezani Tehrani F, Daneshpour M, Hashemi S, Zarkesh M, Azizi F. Relationship between polymorphism of insulin receptor gene, and adiponectin gene with PCOS. Iran J Reprod Med. 2013;11:185–94.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Ranjzad F, Mahmoudi T, Irani Shemirani A, Mahban A, Nikzamir A, Vahedi M, Ashrafi M, Gourabi H. A common variant in the adiponectin gene and polycystic ovary syndrome risk. Mol Biol Rep. 2012;39:2313–9.CrossRefPubMedGoogle Scholar
  29. 29.
    San Millán JL, Cortón M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab. 2004;89:2640–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Xita N, Georgiou I, Chatzikyriakidou A, Vounatsou M, Papassotiriou GP, Papassotiriou I, Tsatsoulis A. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem. 2005;51:416–23.CrossRefPubMedGoogle Scholar
  31. 31.
    Yoshihara K, Yahata T, Kashima K, Mikami T, Tanaka K. Association of single nucleotide polymorphisms in adiponectin and its receptor genes with polycystic ovary syndrome. J Reprod Med. 2009;54:669–74.PubMedGoogle Scholar
  32. 32.
    Zhang N, Shi YH, Hao CF, Gu HF, Li Y, Zhao YR, Wang LC, Chen ZJ. Association of +45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women. Eur J Endocrinol. 2008;158:255–60.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhang W, Wu X, Ding M, Yu X, Liu G, Shi Y. Case-control based study between polymorphisms in the adiponectin gene and polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi. 2015;50:825–9.PubMedGoogle Scholar
  34. 34.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.CrossRefGoogle Scholar
  35. 35.
    Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Xie X, Shi X, Liu M. The roles of TLR gene polymorphisms in atherosclerosis: a systematic review and meta-analysis of 35,317 subjects. Scand J Immunol. 2017;86:50–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Shi X, Xie X, Jia Y, Li S. Associations of insulin receptor and insulin receptor substrates genetic polymorphisms with polycystic ovary syndrome: a systematic review and meta-analysis. J Obstet Gynaecol Res. 2016;42:844–54.CrossRefPubMedGoogle Scholar
  38. 38.
    Xie X, Shi X, Xun X, Rao L. Endothelial nitric oxide synthase gene single nucleotide polymorphisms and the risk of hypertension: a meta-analysis involving 63,258 subjects. Clin Exp Hypertens. 2017;39:175–82.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s). 2018

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of gynaecologyLinyi Central HospitalLinyiChina

Personalised recommendations